Catholic medical center
Seoul, Seocho-gu, South Korea
NCT Number: NCT02103647
The purpose of this study is to compare the pharmacokinetics profiles of pregabalin sustained release tablet (300mg) to immediate release capsule(150mg * 2) while multiple dosing.
Looking for future studies?
Notify Me19 year–44 year
Male
Interventional
Phase 1
Seoul, Seocho-gu, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Immediate release capsule
sustained release tablet
Time frame: 0~4day / 14~18day
Time frame: 0~25day
IlDong Pharmaceutical Co Ltd
Industry
A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02955472
Diabetes Complications, Diabetes Mellitus
Jeonju, Jeollabuk-do, South Korea
View Trial DetailsNCT02952937
Diabetes Complications, Diabetes Mellitus
Jeonju, Jeollabuk-do, South Korea
View Trial DetailsNCT02103686
Healthy, Nervous System Diseases
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details